We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TEAD
2126
Teads Holding Co
TEAD
$64.5M
| $126K | ﹤0.01% |
34,868
-8,284
| -19% | -$32.4K |
|
2127
BRC Inc
BRCC
$216M
| $122K | ﹤0.01% |
19,978
-1,313
| -6% | -$8.57K |
|
2128
Riot Platforms
RIOT
$7.34B
| $122K | ﹤0.01% |
+35,907
| New | +$185K |
|
|
BRFS
2129
DELISTED
BRF SA
BRFS
| $120K | ﹤0.01% |
76,104
-4,390
| -5% | -$9.1K |
|
2130
SIGA Technologies
SIGA
$211M
| $116K | ﹤0.01% |
15,793
-850
| -5% | -$7.45K |
|
2131
Phathom Pharmaceuticals
PHAT
$693M
| $113K | ﹤0.01% |
+10,046
| New | +$104K |
|
2132
Consumer Portfolio Services
CPSS
$199M
| $113K | ﹤0.01% |
12,712
-625
| -5% | -$4.48K |
|
|
SEMR
2133
DELISTED
Semrush
SEMR
| $109K | ﹤0.01% |
13,332
+229
| +2% | +$2.32K |
|
|
ENFN
2134
DELISTED
Enfusion, Inc.
ENFN
| $108K | ﹤0.01% |
+11,210
| New | +$126K |
|
|
HT
2135
DELISTED
Hersha Hospitality Trust Priority Class A Common Shares of Beneficial Interest
HT
| $108K | ﹤0.01% |
12,705
+1,693
| +15% | +$15.2K |
|
|
RCM
2136
DELISTED
R1 RCM Inc. Common Stock
RCM
| $107K | ﹤0.01% |
10,026
-40,911
| -80% | -$519K |
|
2137
Relmada Therapeutics
RLMD
$484M
| $106K | ﹤0.01% |
+30,343
| New | +$266K |
|
2138
Clean Energy Fuels
CLNE
$355M
| $106K | ﹤0.01% |
20,362
+1,482
| +8% | +$9.1K |
|
2139
Xperi
XPER
$332M
| $106K | ﹤0.01% |
+12,294
| New | +$141K |
|
|
KZR
2140
DELISTED
Kezar Life Sciences
KZR
| $105K | ﹤0.01% |
1,485
-102
| -6% | -$7.56K |
|
|
VRAY
2141
DELISTED
ViewRay, Inc.
VRAY
| $101K | ﹤0.01% |
22,504
-62,832
| -74% | -$273K |
|
|
AUY
2142
DELISTED
Yamana Gold, Inc.
AUY
| $99.2K | ﹤0.01% |
17,867
-1,622
| -8% | -$8.2K |
|
2143
Opko Health
OPK
$1.04B
| $97.9K | ﹤0.01% |
78,338
-252,911
| -76% | -$399K |
|
2144
Kinross Gold
KGC
$32.5B
| $96.3K | ﹤0.01% |
23,553
-2,198
| -9% | -$8.69K |
|
|
TSVT
2145
DELISTED
2seventy bio
TSVT
| $95.4K | ﹤0.01% |
+10,811
| New | +$152K |
|
|
LONA
2146
LeonaBio Inc
LONA
$70.5M
| $94.9K | ﹤0.01% |
2,995
-18,952
| -86% | -$597K |
|
2147
LegalZoom.com
LZ
$973M
| $93K | ﹤0.01% |
+12,018
| New | +$104K |
|
2148
Lexicon Pharmaceuticals
LXRX
$1.07B
| $89.8K | ﹤0.01% |
47,014
-253,205
| -84% | -$539K |
|
2149
BARK
BARK
$96.7M
| $88.2K | ﹤0.01% |
+2,960
| New | +$98.5K |
|
|
INFN
2150
DELISTED
Infinera Corporation Common Stock
INFN
| $84.4K | ﹤0.01% |
12,529
-18,115
| -59% | -$110K |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.